Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst consensus estimate of $(3.71) by 2.56 percent. This is a 80.5 percent decrease over losses of $(2.00) per share from the same period last year. The company reported quarterly sales of $1.300 million which missed the analyst consensus estimate of $1.425 million by 8.77 percent. This is a 58.55 percent decrease over sales of $3.136 million the same period last year.